Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | RBBP5 | Q15291 | 5/20 | 0.61 |
| ▸ | DPY30 | Q9C005 | 5/20 | 0.61 |
| ▸ | ASH2L | Q9UBL3 | 5/20 | 0.61 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | RXFP3 | Q9NSD7 | 6/20 | 0.39 |
| ▸ | RXFP4 | Q8TDU9 | 6/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23295928 | 1.00 | WDR5 (0.61) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23295919 | 1.00 | WDR5 (0.61) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL20564830 | 0.94 | WDR5 (0.61) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL20563798 | 0.91 | WDR5 (0.71) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23295837 | 0.91 | WDR5 (0.66) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL20564489 | 0.88 | WDR5 (0.75) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23682876 | 0.87 | WDR5 (0.78) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL15005758 | 0.87 | WDR5 (0.78) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL15004652 | 0.87 | WDR5 (0.78) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL20565531 | 0.86 | WDR5 (0.79) | WDR5KMT2ARBBP5DPY30ASH2L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | UNIV MICHIGAN REGENTS (US) | 2021-05-06 | — | — | US | claimed |
| WO-2018213228-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-11-22 | — | — | WO | claimed |
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | UNIV MICHIGAN REGENTS (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | UNIV MICHIGAN REGENTS (US) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | WDR5, MLLT1, WDR1 | WDR5 1/4885KMT2A 22/4885RBBP5 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.